Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancer
Hossein Fallahi
March 06, 2023
Metastatic relapse after treatment is the leading cause of cancer mortality, and known resistance mechanisms are missing for most treatments administered to patients. To bridge this gap, Pradat et al Paper analyzed a pan-cancer cohort (META-PRISM) of 1,031 refractory metastatic tumors profiled via whole-exome and transcriptome sequencing. They have demonstrated that molecular markers improve six-month survival prediction, particularly in patients with advanced breast cancer.